Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Sep-Oct;18(5):15579883241285162.
doi: 10.1177/15579883241285162.

The Efficacy of Cabazitaxel in Treating Prostate Cancer: A Systematic Review and Meta-Analysis

Hashim Talib Hashim  1 , Mudassir Ahmad Khan  2 , Safa Irfan Shah  3 , Mohammedbaqer Ali Al-Ghuraibawi  1 , Fatimah Abdullah Sulaiman  4 , Jamil Nasrallah  5 , Ralph Maroun  6 , Ali Talib Hashim  7 , Naseer Ahmed  8 , Zahraa Hamaza Merza  9
Affiliations
Meta-Analysis

The Efficacy of Cabazitaxel in Treating Prostate Cancer: A Systematic Review and Meta-Analysis

Hashim Talib Hashim et al. Am J Mens Health. 2024 Sep-Oct.

Abstract

Cabazitaxel, a second-generation taxane chemotherapy agent, has demonstrated efficacy in treating metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received docetaxel-based therapy. By targeting microtubule dynamics, cabazitaxel inhibits cancer cell division and induces apoptosis, thereby extending survival and delaying disease progression in this challenging patient population. A systematic review and meta-analysis were done by searching the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess; OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tools assessment for RCTs. In the analysis, we used RevMan Cochrane software. Our research reveals significantly improved outcomes in terms of patient survival rates, both progression-free survival (PFS) and overall survival (OS), for cabazitaxel over comparative treatment (PFS HR 0.77 [0.61, 0.97]) (OS HR 0.79 [0.70, 0.88]). The treatment response rates were also favorable for cabazitaxel, reported as PSA Reduction Response of more than 50% (PRR) (odds ratio (OR) = 1.59 [0.56, 4.52]) and tumor response rate (TRR) (OR = 2.34 [1.28, 4.28]). Cabazitaxel was associated with significantly more incidence of adverse events. The risk ratio (RR) for serious adverse events was 1.64 [1.14, 2.35] for cabazitaxel compared to the current regimen. A systematic review and meta-analysis were done by searching in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess; OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tools assessment for RCTs. In the analysis, we used RevMan Cochrane software.

Keywords: cabazitaxel; efficacy; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flowchart of the Studies Inclusion Process
Figure 2.
Figure 2.
Progression-Free Survival
Figure 3.
Figure 3.
Overall Survival
Figure 4.
Figure 4.
Serious Adverse Events
Figure 5.
Figure 5.
Prostate-Specific Antigen
Figure 6.
Figure 6.
Tumor Response Rate
Figure 7.
Figure 7.
Mortality
Figure 8.
Figure 8.
Risk of Bias Summary
See this image and copyright information in PMC

References

    1. Annala M., Fu S., Bacon J. V. W., Sipola J., Iqbal N., Ferrario C., Ong M., Wadhwa D., Hotte S. J., Lo G., Tran B., Wood L. A., Gingerich J. R., North S. A., Pezaro C. J., Ruether J. D., Sridhar S. S., Kallio H. M. L., Khalaf D. J., . . .Chi K. N. (2021). Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: A multicentre, randomised, open-label, phase II trial. Annals of Oncology, 32(7), 896–905. - PubMed
    1. Azarenko O., Smiyun G., Mah J., Wilson L., Jordan M. A. (2014). Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Molecular Cancer Therapeutics, 13(8), 2092–2103. - PubMed
    1. Bilusic M., Dahut W. L. (2011). Cabazitaxel: A new drug for metastatic prostate cancer. Asian Journal of Andrology, 13(2), 185–186. - PMC - PubMed
    1. Calcagno F., Nguyen T., Dobi E., Villanueva C., Curtit E., Kim S., Montcuquet P., Kleinclauss F., Pivot X., Thiery-Vuillemin A. (2013). Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clinical Medicine Insights: Oncology, 7, 1–12. - PMC - PubMed
    1. de Bono J. S., Oudard S., Ozguroglu M., Hansen S., Machiels J. P., Kocak I., Gravis G., Bodrogi I., Mackenzie M. J., Shen L., Roessner M., Gupta S., Sartor A. O., & TROPIC Investigators. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. The Lancet, 376(9747), 1147–1154. - PubMed

MeSH terms

LinkOut - more resources